Abbott Laboratories
SIX:ABT
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
|
Abbott Laboratories
NYSE:ABT
|
195.8B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
579.2B USD |
Loading...
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
139.1B USD |
Loading...
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
129.6B USD |
Loading...
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
108.9B USD |
Loading...
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
51.5B USD |
Loading...
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
175B USD |
Loading...
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
45.7B EUR |
Loading...
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
51.9B USD |
Loading...
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
45.2B USD |
Loading...
|
|
| US |
|
Resmed Inc
NYSE:RMD
|
36.9B USD |
Loading...
|
Market Distribution
| Min | -24 813% |
| 30th Percentile | 28.9% |
| Median | 43% |
| 70th Percentile | 60.5% |
| Max | 10 905 714.3% |
Other Profitability Ratios
Abbott Laboratories
Glance View
Nestled into the landscape of global healthcare, Abbott Laboratories emerges as a stalwart that champions scientific innovation and broad accessibility. Established in 1888 by Dr. Wallace Calvin Abbott, the company evolved from a modest medicinal compounding business into a diversified healthcare conglomerate. Today, Abbott's reach extends across more than 160 countries, where it dedicates itself to advancing human health through a wide array of products, including diagnostics, medical devices, nutritionals, and branded generic medicines. This diverse portfolio enables Abbott to remain resilient amid varying market conditions, ensuring its stability and growth are less susceptible to the cyclical nature of any single healthcare segment. Central to Abbott's operations is its prowess in diagnostics and medical devices, both sectors contributing significantly to the company's bottom line. Diagnostics equip healthcare providers with advanced tools to detect diseases early, tailoring treatments to improve patient outcomes—a demand ballooning in tandem with global health awareness. Moreover, Abbott’s innovative medical devices, from cardiovascular to neuromodulation technologies, address some of the most pressing health challenges. Meanwhile, the company’s nutrition products, such as infant formulas and dietary supplements, tap into a burgeoning global appetite for health-conscious living. Each of these ventures feeds into Abbott's strategy of sustaining growth through constant innovation, strategic international expansion, and responsiveness to healthcare trends and needs worldwide. It's this blend of diversification and specialization that keeps the company at the forefront of the healthcare arena.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Abbott Laboratories is 56.7%, which is above its 3-year median of 55.7%.
Over the last 3 years, Abbott Laboratories’s Gross Margin has increased from 56.3% to 56.7%. During this period, it reached a low of 55% on Sep 30, 2023 and a high of 56.7% on Jan 1, 2026.